Dolutegravir-associated hyperglycaemia in patients with HIV
Publication date: Available online 24 February 2020Source: The Lancet HIVAuthor(s): Mohammed Lamorde, Martha Atwiine, Noela C Owarwo, Ahmed Ddungu, Eva O Laker, Frank Mubiru, Agnes Kiragga, Isaac B Lwanga, Barbara Castelnuovo (Source: The Lancet HIV)
Source: The Lancet HIV - February 25, 2020 Category: Infectious Diseases Source Type: research
Point-of-care HIV viral load testing combined with task shifting to improve treatment outcomes (STREAM): findings from an open-label, non-inferiority, randomised controlled trial
Publication date: Available online 24 February 2020Source: The Lancet HIVAuthor(s): Paul K Drain, Jienchi Dorward, Lauren R Violette, Justice Quame-Amaglo, Katherine K Thomas, Natasha Samsunder, Hope Ngobese, Koleka Mlisana, Pravikrishnen Moodley, Deborah Donnell, Ruanne V Barnabas, Kogieleum Naidoo, Salim S Abdool Karim, Connie Celum, Nigel Garrett (Source: The Lancet HIV)
Source: The Lancet HIV - February 25, 2020 Category: Infectious Diseases Source Type: research
Point-of-care HIV testing can help achieve UNAIDS targets
Publication date: Available online 24 February 2020Source: The Lancet HIVAuthor(s): Margaret Hellard, Kathleen E Ryan, Mark Stoové (Source: The Lancet HIV)
Source: The Lancet HIV - February 25, 2020 Category: Infectious Diseases Source Type: research
Correction to Lancet HIV 2020; 7: e84
Publication date: Available online 24 February 2020Source: The Lancet HIVAuthor(s): (Source: The Lancet HIV)
Source: The Lancet HIV - February 25, 2020 Category: Infectious Diseases Source Type: research
Lessons on PrEP from the SEARCH study in east Africa
Publication date: Available online 19 February 2020Source: The Lancet HIVAuthor(s): Connie Celum, Jared M Baeten (Source: The Lancet HIV)
Source: The Lancet HIV - February 20, 2020 Category: Infectious Diseases Source Type: research
Uptake, engagement, and adherence to pre-exposure prophylaxis offered after population HIV testing in rural Kenya and Uganda: 72-week interim analysis of observational data from the SEARCH study
This study is registered with ClinicalTrials.gov, NCT01864603.FindingsBetween June 6, 2016, and June 23, 2017, 70 379 community residents 15 years or older who had not previously been diagnosed with HIV were tested during population-level HIV testing. Of these individuals, 69 121 tested HIV-negative, 12 935 of whom had elevated HIV risk (1353 [10%] serodifferent partnership, 6938 [54%] risk score, 4644 [36%] otherwise self-identified risk). 3489 (27%) initiated PrEP, 2865 (82%) of whom did so on the same day as HIV testing and 1733 (50%) of whom were men. PrEP uptake was lower among individuals aged 15–24 years (ad...
Source: The Lancet HIV - February 20, 2020 Category: Infectious Diseases Source Type: research
Shortening HIV vaccine regimens to achieve high coverage
Publication date: Available online 17 February 2020Source: The Lancet HIVAuthor(s): Maria Blasi, Genevieve G Fouda (Source: The Lancet HIV)
Source: The Lancet HIV - February 18, 2020 Category: Infectious Diseases Source Type: research
Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17–22)
In this study, we evaluated the safety, tolerability, and immunogenicity of shorter, simpler regimens of trivalent Ad26.Mos.HIV expressing mosaic HIV-1 Env/Gag/Pol antigens combined with aluminium phosphate-adjuvanted clade C gp140 protein.MethodsWe did this randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) at Beth Israel Deaconess Medical Center in Boston, MA, USA. We included healthy, HIV-uninfected participants (aged 18–50 years) who were considered at low risk for HIV infection and had not received any vaccines in the 14 days before study commencement. We randomly assigned participants vi...
Source: The Lancet HIV - February 18, 2020 Category: Infectious Diseases Source Type: research
HIV transmission and source–sink dynamics in sub-Saharan Africa
Publication date: Available online 14 February 2020Source: The Lancet HIVAuthor(s): Justin T Okano, Katie Sharp, Eugenio Valdano, Laurence Palk, Sally BlowerSummaryMultiple phylogenetic studies of HIV in sub-Saharan Africa have shown that mobility-driven transmission frequently occurs: many communities export and import strains. Mobility-driven transmission can result in source–sink dynamics: one community can sustain a micro-epidemic in another community in which transmission is too low to be self-sustaining. In epidemiology, the basic reproduction number (R0) is used to specify the sustainability threshold. R0 represen...
Source: The Lancet HIV - February 15, 2020 Category: Infectious Diseases Source Type: research
How universal does universal test and treat have to be?
Publication date: Available online 13 February 2020Source: The Lancet HIVAuthor(s): Rebecca F Baggaley, T Déirdre Hollingsworth (Source: The Lancet HIV)
Source: The Lancet HIV - February 15, 2020 Category: Infectious Diseases Source Type: research
The effect of 90-90-90 on HIV-1 incidence and mortality in eSwatini: a mathematical modelling study
Publication date: Available online 13 February 2020Source: The Lancet HIVAuthor(s): Adam Akullian, Michelle Morrison, Geoffrey P Garnett, Zandile Mnisi, Nomthandazo Lukhele, Daniel Bridenbecker, Anna BershteynSummaryBackgroundThe rapid scale-up of antiretroviral therapy (ART) towards the UNAIDS 90-90-90 goals over the last decade has sparked considerable debate as to whether universal test and treat can end the HIV-1 epidemic in sub-Saharan Africa. We aimed to develop a network transmission model, calibrated to capture age-specific and sex-specific gaps in the scale-up of ART, to estimate the historical and future effect o...
Source: The Lancet HIV - February 15, 2020 Category: Infectious Diseases Source Type: research
Novel approach to scale integrated depression and HIV care
Publication date: Available online 11 February 2020Source: The Lancet HIVAuthor(s): Jerome T Galea, Stephanie Marhefka, Elena Cyrus, Carmen Contreras, Brandon Brown (Source: The Lancet HIV)
Source: The Lancet HIV - February 12, 2020 Category: Infectious Diseases Source Type: research
Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial
Publication date: Available online 6 February 2020Source: The Lancet HIVAuthor(s): Punnee Pitisuttithum, Sorachai Nitayaphan, Suwat Chariyalertsak, Jaranit Kaewkungwal, Peter Dawson, Jittima Dhitavat, Benjaluck Phonrat, Siriwat Akapirat, Nicos Karasavvas, Lindsay Wieczorek, Victoria Polonis, Michael A Eller, Poonam Pegu, Dohoon Kim, Alexandra Schuetz, Surat Jongrakthaitae, Yingjun Zhou, Faruk Sinangil, Sanjay Phogat, Carlos A DiazgranadosSummaryBackgroundThe RV144 phase 3 vaccine trial in Thailand demonstrated that ALVAC-HIV (vCP1521) and AIDSVAX B/E administration over 6 months resulted in a 31% efficacy in preventing HIV...
Source: The Lancet HIV - February 7, 2020 Category: Infectious Diseases Source Type: research
Correction to Lancet HIV 2020; published online Jan 14. https://doi.org/10.1016/S2352-3018(19)30378-9
Publication date: Available online 6 February 2020Source: The Lancet HIVAuthor(s): (Source: The Lancet HIV)
Source: The Lancet HIV - February 7, 2020 Category: Infectious Diseases Source Type: research
Vaccine boosts: balancing response magnitude and character
Publication date: Available online 6 February 2020Source: The Lancet HIVAuthor(s): Andrew R Crowley, Margaret E Ackerman (Source: The Lancet HIV)
Source: The Lancet HIV - February 7, 2020 Category: Infectious Diseases Source Type: research
